B Cell Lymphoma
From the Journals
Heed cardiac risk of BTKis for CLL
New consensus statement warns about cardiac risk of using BTKis, but a cardio-oncologist specialist questions its conclusions.
Feature
Drug shortages plague hematology, but preparedness helps
The plight of desperate patients is getting attention – and some remedies.
News
FDA approves liso-cel as second-line therapy for LBCL
Liso-cel could now become a “new standard of care for patients after failure of first-line therapy,” offering significantly improved outcomes for...
Conference Coverage
Novel gene therapy offers hope for some lymphomas
Novel CAR T-cell product shows promise for second-line treatment of relapsed and refractory lymphoma patients in a pilot study.
Conference Coverage
Glofitamab prevails against r/r DLBCL
Additional longer-term data showed a strong safety profile and promising long-term remission.
Latest News
‘Exciting’ new gene therapy yields promising results
A single dose of CAR-T cell therapy evoked a beneficial response in patients with relapsed or refractory non-Hodgkin lymphoma.
Feature
Third-generation Black woman physician makes cancer research history
African American surgeon helped found ASCO and collaborated with her father to achieve lasting breakthroughs in chemotherapy.
Feature
Ex–hospital porter a neglected giant of cancer research
An Indian immigrant who once emptied bedpans in a Boston hospital went on to become the “father of chemotherapy.”
Feature
Repurposed drug could revolutionize stem cell transplantation
Abatacept to prevent for acute graft-versus-host disease is a game changer for patients receiving hematopoietic stem cell transplants who lack...
Latest News
EMA gives green light to new CAR T-cell therapy
The committee also recommended approval of a biosimilar product for pegfilgrastim.
Feature
100 coauthored papers, 10 years: Cancer transplant pioneers model 'team science'
MSKCC medical oncologists share expertise in HSCT, Spanish background, a gift for mentoring, and 100 peer-reviewed publications written together...